Melanoma PNL2

PNL2, Ms

Technische Daten
Change(s) made:Complete revision
Status:In Vitro Diagnostic Use (IVD)
Ig Unterklasse:IgG1
Vorbehandlung:ProTaqs® Antigen Enhancer I (Cat. No. 401602092) or ProTaqs® Antigen Enhancer IV (Cat. No. 401602392)
Zelluläre Lokalisation:Cytoplasmic
Synonyme:Antigen LB39 AA, Antigen SK29 AA, CMM 1, CMM, CMM1, Cutaneous Malignant Melanoma Dysplastic Nevus, Dysplastic Nevus Syndrome, FAMMM, MART1, melan A, Melan A protein, Melanoma antigen recognized by T-cells 1, MLM, Monophenol monooxygenase, Tumor rejection antigen AB, tyrosinase
Verfügbar in folgenden Ländern:worldwide

PNL2 is a novel monoclonal antibody that labels melanocytes in the cytoplasm and plasma membrane and tumors derived from these cells (melanomas and clear cell sarcomas). Antibodies against PNL2, Melan-A and HMB-45 stain most clear cell sarcoma cells and a few cells in angiomyolipomas and lymphangioleiomyomatosis; a panel of antibodies, including HMB-45, MART-1, Tyrosinase, and MiTF enables differential diagnosis. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma, and combined with antibodies against S-100 and HMB-45 is a highly sensitive and specific marker for mucosal melanoma.